Schedule 13D ownership disclosure

Avalo Therapeutics, Inc.

Security class unavailable · CUSIP: 05338F108

Event date: 2022-03-14

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
Unavailable
Percent of class
44.2000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001193125-22-076294
Form type
SC 13D/A
Filer
ARMISTICE CAPITAL, LLC
CIK
CIK 1601086
Filed
Mar 15, 2022
Reporting period
Mar 14, 2022
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub